Sigma-Tau Group

Sigma-Tau is a leading, Italian capital, international pharmaceutical group that invests in the research, development and marketing of innovative and effective treatments to improve human well-being and quality of life. Sigma-Tau Group has headquarters in Pomezia (Rome, Italy), and subsidiaries in the USA, EU and China, and production plants in Italy as well as in Spain and US (Indianapolis). With over 2000 employees and an extensive network of licensees worldwide, Sigma-Tau achieved a global turnover of € 688 million in 2012. A dedicated Global Rare Disease Franchise was recently established to focus on the global development and commercialization of medicines for patients with rare diseases. The products are dedicated to onco-hematological diseases and certain genetic disorders. With more than 7,000 identified rare diseases, Sigma-Tau places its considerable scientific resources behind the development and commercialization of compounds that benefit the few. The R&D projects in the pipeline are currently focused on the following therapeutic areas: Rare and Neglected Diseases, Oncology/Immuno-oncology, Biotechnology and at line extensions. Sigma-Tau R&D is also active in Nutraceuticals and Medical Food.